Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial.

Danko JR, Kochel T, Teneza-Mora N, Luke TC, Raviprakash K, Sun P, Simmons M, Moon JE, De La Barrera R, Martinez LJ, Thomas SJ, Kenney RT, Smith L, Porter KR.

Am J Trop Med Hyg. 2018 Mar;98(3):849-856. doi: 10.4269/ajtmh.17-0416. Epub 2018 Jan 18.

2.

Racial and Ethnic Variation in Health-Related Quality of Life Scores Prior to Prostate Cancer Treatment.

Reading SR, Porter KR, Slezak JM, Harrison TN, Gelfond JS, Chien GW, Jacobsen SJ.

Sex Med. 2017 Dec;5(4):e219-e228. doi: 10.1016/j.esxm.2017.07.002. Epub 2017 Aug 18.

3.

NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients.

Sun P, Morrison BJ, Beckett CG, Liang Z, Nagabhushana N, Li A, Porter KR, Williams M.

J Immunol Methods. 2017 Feb;441:24-30. doi: 10.1016/j.jim.2016.11.005. Epub 2016 Nov 14.

PMID:
27856192
4.

DNA Vaccine Delivery and Improved Immunogenicity.

Porter KR, Raviprakash K.

Curr Issues Mol Biol. 2017;22:129-138. doi: 10.21775/cimb.022.129. Epub 2016 Nov 10. Review.

PMID:
27831541
5.

Targeted next generation sequencing approach identifies eighteen new candidate genes in normosmic hypogonadotropic hypogonadism and Kallmann syndrome.

Quaynor SD, Bosley ME, Duckworth CG, Porter KR, Kim SH, Kim HG, Chorich LP, Sullivan ME, Choi JH, Cameron RS, Layman LC.

Mol Cell Endocrinol. 2016 Dec 5;437:86-96. doi: 10.1016/j.mce.2016.08.007. Epub 2016 Aug 5.

PMID:
27502037
6.

Racial and Ethnic Variation in Time to Prostate Biopsy After an Elevated Screening Level of Serum Prostate-specific Antigen.

Reading SR, Porter KR, Hsu JY, Wallner LP, Loo RK, Jacobsen SJ.

Urology. 2016 Oct;96:121-127. doi: 10.1016/j.urology.2016.06.008. Epub 2016 Jun 15.

PMID:
27316374
7.

The Epidemiology, Virology and Clinical Findings of Dengue Virus Infections in a Cohort of Indonesian Adults in Western Java.

Kosasih H, Alisjahbana B, Nurhayati, de Mast Q, Rudiman IF, Widjaja S, Antonjaya U, Novriani H, Susanto NH, Jusuf H, van der Ven A, Beckett CG, Blair PJ, Burgess TH, Williams M, Porter KR.

PLoS Negl Trop Dis. 2016 Feb 12;10(2):e0004390. doi: 10.1371/journal.pntd.0004390. eCollection 2016 Feb.

8.

Nucleic acid (DNA) immunization as a platform for dengue vaccine development.

Porter KR, Raviprakash K.

Vaccine. 2015 Dec 10;33(50):7135-40. doi: 10.1016/j.vaccine.2015.09.102. Epub 2015 Oct 14. Review.

PMID:
26458805
9.

Variability in date of prostate cancer diagnosis: a comparison of cancer registry, pathology report, and electronic health data sources.

Porter KR, Chao C, Quinn VP, Hsu JW, Jacobsen SJ.

Ann Epidemiol. 2014 Nov;24(11):855-60. doi: 10.1016/j.annepidem.2014.09.004. Epub 2014 Sep 17.

PMID:
25282324
10.

Tetravalent DNA vaccine product as a vaccine candidate against dengue.

Porter KR, Teneza-Mora N, Raviprakash K.

Methods Mol Biol. 2014;1143:283-95. doi: 10.1007/978-1-4939-0410-5_17.

PMID:
24715294
11.

Assessment of clinical and nonclinical characteristics associated with health-related quality of life in patients with high-grade gliomas: a feasibility study.

Porter KR, Menon U, Vick NA, Villano JL, Berbaum ML, Davis FG.

Support Care Cancer. 2014 May;22(5):1349-62. doi: 10.1007/s00520-013-2093-z. Epub 2014 Jan 3.

12.

Evidence for endemic chikungunya virus infections in Bandung, Indonesia.

Kosasih H, de Mast Q, Widjaja S, Sudjana P, Antonjaya U, Ma'roef C, Riswari SF, Porter KR, Burgess TH, Alisjahbana B, van der Ven A, Williams M.

PLoS Negl Trop Dis. 2013 Oct 24;7(10):e2483. doi: 10.1371/journal.pntd.0002483. eCollection 2013.

13.

Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.

Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG.

BJU Int. 2013 May;111(6):954-62. doi: 10.1111/j.1464-410X.2012.11639.x. Epub 2013 Mar 6.

14.

Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy.

Chao C, Williams SG, Xu L, Chen J, Wallner LP, Porter KR, Jacobsen SJ.

Cancer Lett. 2013 Jul 10;335(1):214-8. doi: 10.1016/j.canlet.2013.02.017. Epub 2013 Feb 16.

PMID:
23419526
15.

Racial and ethnic differences in time to treatment for patients with localized prostate cancer.

Porter KR, Hsu JW, Chien GW, Xiang AH, Jung H, Chao C, Jacobsen SJ.

Urology. 2013 Feb;81(2):283-7. doi: 10.1016/j.urology.2012.11.002.

PMID:
23374784
16.

Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.

Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, Teneza-Mora N, Raviprakash K.

Vaccine. 2012 Jan 5;30(2):336-41. doi: 10.1016/j.vaccine.2011.10.085. Epub 2011 Nov 12.

PMID:
22085548
17.

Development of dengue DNA vaccines.

Danko JR, Beckett CG, Porter KR.

Vaccine. 2011 Sep 23;29(42):7261-6. doi: 10.1016/j.vaccine.2011.07.019. Epub 2011 Jul 21. Review.

PMID:
21777640
18.

Conditional survival of all primary brain tumor patients by age, behavior, and histology.

Porter KR, McCarthy BJ, Berbaum ML, Davis FG.

Neuroepidemiology. 2011;36(4):230-9. doi: 10.1159/000327752. Epub 2011 Jun 16.

19.

Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.

Maves RC, Oré RM, Porter KR, Kochel TJ.

Vaccine. 2011 Mar 24;29(15):2691-6. doi: 10.1016/j.vaccine.2011.01.077. Epub 2011 Feb 17.

PMID:
21303709
20.

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.

Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, Wu SJ, Sun P, Kochel T, Raviprakash K, Hayes CG, Porter KR.

Vaccine. 2011 Jan 29;29(5):960-8. doi: 10.1016/j.vaccine.2010.11.050. Epub 2010 Nov 25.

PMID:
21111785
21.

Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina.

Engelhard HH, Villano JL, Porter KR, Stewart AK, Barua M, Barker FG, Newton HB.

J Neurosurg Spine. 2010 Jul;13(1):67-77. doi: 10.3171/2010.3.SPINE09430.

PMID:
20594020
22.

Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology.

Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG.

Neuro Oncol. 2010 Jun;12(6):520-7. doi: 10.1093/neuonc/nop066. Epub 2010 Feb 8.

23.

Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.

Maves RC, Castillo Oré RM, Porter KR, Kochel TJ.

Clin Vaccine Immunol. 2010 Feb;17(2):304-6. doi: 10.1128/CVI.00353-09. Epub 2009 Dec 9.

24.

Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2.

Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, Comach G, Rose RC, Jin X, Schlesinger JJ.

Clin Vaccine Immunol. 2009 Feb;16(2):285-7. doi: 10.1128/CVI.00363-08. Epub 2008 Nov 26. Erratum in: Clin Vaccine Immunol. 2013 Jun;20(6):954. Rodrigo, W W I S [corrected to Rodrigo, W W Shanaka I].

25.

Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus.

Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, Liang Z, Subramanian H, Porter KR, Sun W, Burgess TH.

Virology. 2009 Jan 20;383(2):207-15. doi: 10.1016/j.virol.2008.10.022. Epub 2008 Nov 17.

26.

Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.

Villano JL, Propp JM, Porter KR, Stewart AK, Valyi-Nagy T, Li X, Engelhard HH, McCarthy BJ.

Neuro Oncol. 2008 Apr;10(2):121-30. doi: 10.1215/15228517-2007-054. Epub 2008 Feb 20.

27.

Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.

Raja NU, Holman DH, Wang D, Raviprakash K, Juompan LY, Deitz SB, Luo M, Zhang J, Porter KR, Dong JY.

Am J Trop Med Hyg. 2007 Apr;76(4):743-51.

PMID:
17426182
28.

A multisolute osmotic virial equation for solutions of interest in biology.

Elliott JA, Prickett RC, Elmoazzen HY, Porter KR, McGann LE.

J Phys Chem B. 2007 Feb 22;111(7):1775-85. Epub 2007 Feb 1.

PMID:
17266364
29.

Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.

Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J, Porter KR, Dong JY.

Clin Vaccine Immunol. 2007 Feb;14(2):182-9. Epub 2006 Dec 27.

30.

Needle-free injection of DNA vaccines: a brief overview and methodology.

Raviprakash K, Porter KR.

Methods Mol Med. 2006;127:83-9. Review.

PMID:
16988448
32.

The submicroscopic morphology of protoplasm. 1956.

Porter KR.

Anat Rec A Discov Mol Cell Evol Biol. 2005 Dec;287(2):1186-204. No abstract available.

PMID:
16552845
33.

Four dengue virus serotypes found circulating during an outbreak of dengue fever and dengue haemorrhagic fever in Jakarta, Indonesia, during 2004.

Suwandono A, Kosasih H, Nurhayati, Kusriastuti R, Harun S, Ma'roef C, Wuryadi S, Herianto B, Yuwono D, Porter KR, Beckett CG, Blair PJ.

Trans R Soc Trop Med Hyg. 2006 Sep;100(9):855-62. Epub 2006 Feb 28.

PMID:
16507313
34.

An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies.

Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, Marovich MA, Sun W, Porter KR, Burgess TH.

J Virol Methods. 2006 Jun;134(1-2):74-85. Epub 2006 Jan 18.

PMID:
16417930
35.

Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys.

Blair PJ, Kochel TJ, Raviprakash K, Guevara C, Salazar M, Wu SJ, Olson JG, Porter KR.

Vaccine. 2006 Feb 27;24(9):1427-32. Epub 2005 Sep 27.

PMID:
16214271
36.

Early detection of dengue infections using cluster sampling around index cases.

Beckett CG, Kosasih H, Faisal I, Nurhayati, Tan R, Widjaja S, Listiyaningsih E, Ma'roef C, Wuryadi S, Bangs MJ, Samsi TK, Yuwono D, Hayes CG, Porter KR.

Am J Trop Med Hyg. 2005 Jun;72(6):777-82.

PMID:
15967759
37.

Epidemiology of dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung, West Java, Indonesia.

Porter KR, Beckett CG, Kosasih H, Tan RI, Alisjahbana B, Rudiman PI, Widjaja S, Listiyaningsih E, Ma'Roef CN, McArdle JL, Parwati I, Sudjana P, Jusuf H, Yuwono D, Wuryadi S.

Am J Trop Med Hyg. 2005 Jan;72(1):60-6.

PMID:
15728868
38.

Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys.

Kochel TJ, Watts DM, Gozalo AS, Ewing DF, Porter KR, Russell KL.

J Infect Dis. 2005 Mar 15;191(6):1000-4. Epub 2005 Jan 31.

PMID:
15717278
39.

A serological study of Chikungunya virus transmission in Yogyakarta, Indonesia: evidence for the first outbreak since 1982.

Porter KR, Tan R, Istary Y, Suharyono W, Sutaryo, Widjaja S, Ma'Roef C, Listiyaningsih E, Kosasih H, Hueston L, McArdle J, Juffrie M.

Southeast Asian J Trop Med Public Health. 2004 Jun;35(2):408-15.

PMID:
15691147
40.

Enhancing knowledge and awareness of dengue during a prospective study of dengue fever.

Beckett CG, Kosasih H, Tan R, Widjaja S, Listianingsih E, Ma'roef C, Wuryadi S, Alisjahbana B, Rudiman I, McArdle JL, Porter KR.

Southeast Asian J Trop Med Public Health. 2004 Sep;35(3):614-7.

PMID:
15689076
41.

Influenza surveillance in Indonesia: 1999-2003.

Beckett CG, Kosasih H, Ma'roef C, Listiyaningsih E, Elyazar IR, Wuryadi S, Yuwono D, McArdle JL, Corwin AL, Porter KR.

Clin Infect Dis. 2004 Aug 15;39(4):443-9. Epub 2004 Jul 22.

PMID:
15356802
42.

Identification of Seoul hantavirus in Rattus norvegicus in Indonesia.

Plyusnina A, Ibrahim IN, Winoto I, Porter KR, Gotama IB, Lundkvist A, Vaheri A, Plyusnin A.

Scand J Infect Dis. 2004;36(5):356-9.

PMID:
15287380
43.

Factors predictive of outcome after use of the Ponseti method for the treatment of idiopathic clubfeet.

Dobbs MB, Rudzki JR, Purcell DB, Walton T, Porter KR, Gurnett CA.

J Bone Joint Surg Am. 2004 Jan;86-A(1):22-7.

PMID:
14711941
44.
45.

Transmission of epidemic dengue hemorrhagic fever in easternmost Indonesia.

Sukri NC, Laras K, Wandra T, Didi S, Larasati RP, Rachdyatmaka JR, Osok S, Tjia P, Saragih JM, Hartati S, Listyaningsih E, Porter KR, Beckett CG, Prawira IS, Punjabi N, Suparmanto SA, Beecham HJ, Bangs MJ, Corwin AL.

Am J Trop Med Hyg. 2003 May;68(5):529-35.

PMID:
12812338
46.

Characterization of Norwalk-like virus associated with gastroenteritis in Indonesia.

Subekti DS, Tjaniadi P, Lesmana M, Simanjuntak C, Komalarini S, Digdowirogo H, Setiawan B, Corwin AL, Campbell JR, Porter KR, Oyofo BA.

J Med Virol. 2002 Jun;67(2):253-8.

PMID:
11992587
47.

Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.

Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS.

Virology. 2001 Nov 10;290(1):74-82.

48.

Experimental infection of Macaca nemestrina with a Toronto Norwalk-like virus of epidemic viral gastroenteritis.

Subekti DS, Tjaniadi P, Lesmana M, McArdle J, Iskandriati D, Budiarsa IN, Walujo P, Suparto IH, Winoto I, Campbell JR, Porter KR, Sajuthi D, Ansari AA, Oyofo BA.

J Med Virol. 2002 Mar;66(3):400-6.

PMID:
11793394
49.

Development and evaluation of serotype- and group-specific fluorogenic reverse transcriptase PCR (TaqMan) assays for dengue virus.

Callahan JD, Wu SJ, Dion-Schultz A, Mangold BE, Peruski LF, Watts DM, Porter KR, Murphy GR, Suharyono W, King CC, Hayes CG, Temenak JJ.

J Clin Microbiol. 2001 Nov;39(11):4119-24.

50.

Supplemental Content

Loading ...
Support Center